Hairpin Nucleic Acid Molecules for Interferon Induction in SARS-CoV-2 Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies for COVID-19, particularly in immunocompromised patients, are inadequate due to suboptimal humoral immune responses and the emergence of variants with enhanced transmissibility and antibody evasion, necessitating prophylactic and therapeutic antiviral strategies that provide cross-variant protection.
Innovation Solution
Administration of a nucleic acid molecule with a double-stranded section of less than 19 base pairs that induces type I interferon production, offering a method for treating, preventing, and minimizing viral infections, including those caused by SARS-CoV-2 variants, through pre-exposure or post-exposure prophylaxis and reducing infection severity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccines and antiviral treatments are used, then protection against SARS-CoV-2 is provided, but immunocompromised patients exhibit suboptimal humoral immune responses and fail to clear persistent infections
Solution Approach 1:
The patent introduces type I interferon as an intermediary substance that mediates antiviral activity independently of adaptive immunity. The nucleic acid molecule (polyIC) acts as a mediator to stimulate endogenous type I interferon production, which then provides broad-spectrum antiviral protection without requiring functional B cells or antibodies, thereby solving the problem of treatment failure in immunocompromised patients
Solution Approach 2:
The patent replaces the mechanical/chemical system of antibody-mediated neutralization with a biological signaling system based on type I interferon induction. Instead of relying on adaptive immune mechanisms (antibody production), the invention activates innate immune pathways through RIG-I recognition of dsRNA, substituting a different immunological mechanism that remains functional in immunocompromised states
2Reliability
If long-term antiviral therapy is administered to immunocompromised patients, then viral clearance may be achieved, but continuous intra-host viral evolution occurs leading to immune-evasive variants
Solution Approach 1:
The patent applies preliminary action by establishing strong type I interferon-mediated antiviral pressure early in the treatment course. This initial intense interferon response rapidly reduces viral loads and limits the time window for viral evolution, preventing the emergence of resistant variants before they can develop under prolonged selective pressure
Solution Approach 2:
The patent employs periodic administration of the nucleic acid molecule (polyIC) to maintain sustained type I interferon production. This periodic stimulation creates repeated waves of antiviral activity that continuously suppress viral replication cycles, limiting opportunities for viral evolution while maintaining viral clearance over time
3Reliability
If approved vaccines are administered, then prevention of severe disease is achieved in individuals with intact immune systems, but immunogenicity is significantly attenuated in immunocompromised patients
Solution Approach 1:
The patent uses type I interferon as an intermediary that bridges the gap between vaccination and protective immunity in immunocompromised patients. The nucleic acid molecule stimulates endogenous interferon production, which then provides the protective effect that vaccines fail to generate in these patients, acting as an alternative mediator of immune protection
Solution Approach 2:
The patent changes the immunological parameter from adaptive immunity (antibody-mediated) to innate immunity (interferon-mediated). By shifting the mechanism of protection from B-cell dependent to interferon-dependent pathways, the treatment remains effective across different immunocompetent states, including immunocompromised conditions where adaptive immunity is impaired
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nucleic acid molecule effectively induces type I interferon production, providing broad-spectrum protection against SARS-CoV-2 variants, including those with altered immunogenicity and resistance to antibody binding, thereby reducing viral replication and severity of symptoms.
Implementation Method 1
administering induces type I interferon production in at least one cell of the subject
Implementation Method 2
RIG-I (retinoic acid-inducible gene I) is a cytosolic pattern recognition receptor (PRR) responsible for the type-1 interferon (IFN1) response
Implementation Method 3
RIG-I plays a key role in the innate immune system response to infection by a foreign organism, such as a bacterium or a virus
Implementation Method 4
IFN1s have three main functions: to limit the virus from spreading to nearby cells, promote an innate immune response, including inflammatory responses
Implementation Method 5
The nucleic acid molecule effectively induces type I interferon production, providing broad-spectrum protection against SARS-CoV-2 variants
Data Source
AI summary
The present disclosure provides small hairpin nucleic acid molecules capable of stimulating interferon production. The nucleic acid molecules of the present disclosure has a double-stranded section of less than 19 base pairs and at least one blunt end. In certain embodiments, the molecule comprises at least one 5′-triphosphate and/or at least one 5′-diphosphate. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection, and/or ameliorating, minimizing, reversing, and/or preventing persistent SARS-CoV-2 viral infection, and/or minimizing or preventing SARS-CoV-2 viral infection-derived mortality and/or lethality, in a subject. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection in a tumor-bearing subject. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection in an immune-compromised and/or immunodeficient subject.